Adopting the final Annual Report

November 11, 2024
Language flag

PHI intends to convene a general meeting to adopt the annual report for the fiscal year 2023/2024 and to amend resolutions regarding election of board members and the number of board members.

It has come to the attention of Phase Holographic Imaging PHI AB (publ) (“PHI” or the “Company”) that the annual report for the fiscal year 2023/2024 that was made available and presented at the annual general meeting held on 31 October 2024 was not the final and audited version. Furthermore, Leland Foster has declined to be reelected to the board.

The correct and audited annual report for the fiscal year 2023/2024 has today been published. The Company will shortly issue a notice for an extraordinary general meeting in order to adopt the annual report and to determine the number of board members and the composition of the board of the Company.

Subscribe to PHI news on cision.com

Latest News

Notice of extraordinary general meeting in Phase Holographic Imaging PHI AB 2 December 2024

Phase Holographic Imaging PHI AB (publ), 556542-7811 (the “Company”) will hold an Extraordinary General Meeting on 2 December 2024 at 15.00 CET at the Company’s premises, Skiffervägen 48 in Lund.

PHI resolves on a fully secured rights issue of shares of approximately SEK 64.3 million

The Board of Directors of Phase Holographic Imaging PHI AB has today resolved on a rights issue of shares, with preferential rights for the Company’s existing shareholders, of approximately SEK 64.3 million before deduction of issue related costs, subject to approval by the extraordinary general meeting to be held on 2 December 2024. The purpose of the Rights Issue is to fund a strategic development plan and to strengthen the Company’s capital structure by repayment/off-setting of outstanding loans.
phi-right-moment-to-capitalize-on-regenerative-medicine-momentum

BioStock: PHI’s new CEO: “I am excited to lead us forward with new energy”

Anders Månsson was recently appointed CEO of Phase Holographic Imaging. With extensive leadership experience in the international life sciences sector, he aims to expand PHI’s global reach and position the company as a leader in non-invasive cell quality control technologies. BioStock spoke with him about his vision for the future.
See All News